{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-05T13:24:47.330916+00:00","company":{"ticker":"BIOA","cik":1709941,"company_name":"BioAge Labs, Inc."},"pagination":{"limit":100,"returned":2,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"earnings_release","fact_key":"81a94f7dde897c8f96477f90afb90c857ee9fa5d","cik":1709941,"ticker":"BIOA","company_name":"BioAge Labs, Inc.","filed_at":"2026-05-08T23:59:59+00:00","payload":{"eps_text":"-0.52","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"-22.3 million","period_text":"first quarter ended March 31, 2026","report_date":"2026-05-08","result_type":"reported_results","revenue_text":"2.8 million"},"claim":"BioAge Labs, Inc. reported first quarter ended March 31, 2026 results: revenue 2.8 million, net income -22.3 million, EPS -0.52.","evidence_excerpt":"with Lilly ExploR&D for the development of therapeutic antibodies targeting novel metabolic aging targets. First Quarter 2026 Financial Results Collaboration revenue was $2.8 million for the quarter ended March 31, 2026, compared to $1.5 million for the same period in 2025. The $1.3 million increase in collaboration revenue was due to increased full-time","confidence":0.98,"filing_url":"https://secwatch.observer/filing/0001193125-26-213472","anchor_url":"https://secwatch.observer/filing/0001193125-26-213472#claim-81a94f7dde897c8f96477f90afb90c857ee9fa5d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1709941/000119312526213472/0001193125-26-213472-index.htm"},{"fact_type":"material_agreement","fact_key":"2f89fb019d1114e39b57e53add1847fae1e9adda","cik":1709941,"ticker":"BIOA","company_name":"BioAge Labs, Inc.","filed_at":"2026-01-22T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Underwriting Agreement","agreement_type":"underwriting","counterparty":"Goldman Sachs & Co. LLC, Piper Sandler & Co. and Citigroup Global Markets Inc. as representatives of the underwriters","effective_date":"2026-01-21","item_codes_triggered":["1.01"],"value_text":"$107.6 million"},"claim":"BioAge Labs, Inc. entered into Underwriting Agreement with Goldman Sachs & Co. LLC, Piper Sandler & Co. and Citigroup Global Markets Inc. as representatives of the underwriters valued at $107.6 million (effective 2026-01-21).","evidence_excerpt":"On January 21, 2026, BioAge Labs, Inc., a Delaware corporation (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Goldman Sachs & Co. LLC, Piper Sandler & Co. and Citigroup Global Markets Inc. as representatives of the underwriters named therein (the “ Underwriters ”), pursuant to which the Company agreed to issue and sell 5,897,435 shares (the “ Underwritten Shares ”) of its common stock, par value $0.00001 per share (“ Common Stock ”) to the Underwriters in a public offering at a price of $19.50 per Underwritten Share (the “ Offering ”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-019536","anchor_url":"https://secwatch.observer/filing/0001193125-26-019536#claim-2f89fb019d1114e39b57e53add1847fae1e9adda","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1709941/000119312526019536/0001193125-26-019536-index.htm"}]}